NCT05032404 - Blue Note Therapeutics Product BNT 103 Usability and User Engagement | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

October 26, 2021

Study Completion Date

December 31, 2021

Conditions

Breast Cancer Female

Interventions

DEVICE

BNT103

BNT-103™ is a prescription digital therapeutic specifically designed to treat the symptoms of anxiety and depression related to cancer. There are 10 sessions provided over approximately 10 weeks.

Trial Locations (1)

93065

Blue Note Therapeutics, San Francisco